Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Notes Payables (2023 - 2025)

Historic Notes Payables for Lucid Diagnostics (LUCD) over the last 3 years, with Q3 2025 value amounting to $22.3 million.

  • Lucid Diagnostics' Notes Payables rose 11862.75% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 11862.75%. This contributed to the annual value of $18.6 million for FY2024, which is 3333.33% up from last year.
  • According to the latest figures from Q3 2025, Lucid Diagnostics' Notes Payables is $22.3 million, which was up 11862.75% from $25.3 million recorded in Q2 2025.
  • Over the past 5 years, Lucid Diagnostics' Notes Payables peaked at $32.8 million during Q1 2025, and registered a low of $10.2 million during Q3 2024.
  • For the 3-year period, Lucid Diagnostics' Notes Payables averaged around $16.9 million, with its median value being $14.0 million (2023).
  • As far as peak fluctuations go, Lucid Diagnostics' Notes Payables tumbled by 2960.66% in 2024, and later soared by 14961.95% in 2025.
  • Lucid Diagnostics' Notes Payables (Quarter) stood at $14.0 million in 2023, then surged by 33.33% to $18.6 million in 2024, then grew by 19.89% to $22.3 million in 2025.
  • Its last three reported values are $22.3 million in Q3 2025, $25.3 million for Q2 2025, and $32.8 million during Q1 2025.